A retrospective cohort study published in the Journal of the American Heart Association reports that GLP-1 receptor agonist use was associated with lower risks of heart attack, heart failure and all-cause death among adults with serious mental illness, type 2 diabetes and obesity. The analysis covered 218,043 matched adults drawn from the TriNetX database across 73 health care organizations.

GLP-1 receptor agonists are the drug class that includes semaglutide and tirzepatide, now widely prescribed for type 2 diabetes and obesity. Their cardiometabolic effects are well documented in the general population, but the authors note that their effects in serious mental illness have been unclear, which is the gap this paper sets out to fill.

Why this group is understudied

Adults with serious mental illness who also have diabetes and obesity carry elevated cardiovascular risk, and everyone in this cohort was on active antipsychotic or antidepressant medication. That combination tends to get excluded from clean trial populations, which is exactly why a 218,000-person administrative dataset is doing work here that a randomized trial has not.

Key results

Using propensity score matching against nonusers, the researchers reported risk differences at 1 and 3 years of -0.007 and -0.010 for myocardial infarction, -0.011 and -0.018 for heart failure, and -0.039 and -0.065 for all-cause death, all at P below 0.001. The death figures are the largest of the three, and they are the ones worth sitting with: a 3-year absolute risk difference of -0.065 in a population this size is not a rounding error.

Secondary analyses looking specifically at semaglutide or tirzepatide found the same pattern across all three outcomes. Results stayed directionally consistent after accounting for SGLT2 inhibitor and DPP-4 inhibitor use, which addresses the obvious objection that another diabetes drug class was doing the work.

Limitations

This is a retrospective database study, not a trial, so it establishes association and nothing stronger. The authors themselves say the pooled associations should be read in the context of serious mental illness being clinically heterogeneous, and they flag the limitations of administrative case ascertainment: outcomes here come from coded records, not adjudicated events. Analyses of sex, race and other drug classes were labeled exploratory.

Bottom line

The authors conclude that users in this population had significantly reduced 1- and 3-year risks of heart attack, heart failure and death compared with nonusers. What remains unsettled is whether a matched cohort can carry that finding on its own, or whether this population finally gets a trial of its own.